ProblemIndependent GI groups lose weeks between deciding on an IBD biologic and booking the first infusion. A 2022 pediatric IBD study found prior auth added 10.2 days and complicated cases added 24.6 days, while an ACG survey found half of GI clinicians had seen serious adverse events from PA delays.
SolutionDoseClear GI gives infusion coordinators a first-dose clearance queue that catches missing step-therapy proof, payer-mandated biosimilar swaps, site-of-care redirects, expired screening labs, and incomplete copay packets before the scheduler promises a chair.
Market opportunityCDC says US IBD prevalence now sits between 2.4 and 3.1 million and annual healthcare costs hit $8.5B. Grand View Research pegs the US IBD treatment market at $13.12B, while GI software budgets already run about $400-800 per provider per month.